Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency

INTRODUCTION: In murine cancer models, B cells are unnecessary for efficacy of PD-1 inhibitor. However, we do not know whether this applies to clinical settings, especially in patients with non-small-cell lung carcinoma (NSCLC). CASE PRESENTATION: We report on the case of an advanced lung adenocarci...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Shumin, Hu, Xiufeng, Zhao, Yanqiu, Wang, Zibing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681247/
https://www.ncbi.nlm.nih.gov/pubmed/33240259
http://dx.doi.org/10.3389/fimmu.2020.563622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7681247/
https://www.ncbi.nlm.nih.gov/pubmed/33240259
http://dx.doi.org/10.3389/fimmu.2020.563622

Ejemplares similares